Taste and nutrition company Kerry has announced that it has made two new acquisitions: biotechnology company c-LEcta and Mexican-based enzyme manufacturer Enmex.
c-LEcta specialises in precision fermentation, optimised bio-processing and bio-transformation for the creation of high-value targeted enzymes and ingredients. Based in Germany and employing over 100 people, c-LEcta has a portfolio of bioactives across food, beverage and other consumer markets.
Enmex supplies multiple bio-process solutions for food, beverage and animal nutrition markets. The company also has an enzyme portfolio and a manufacturing infrastructure, which Kerry said will extend its fermentation and enzyme manufacturing capabilities into Latin America.
Commenting on the agreement with c-LEcta, Dr Albert McQuaid, chief science and technology officer of Kerry, said that the acquisitions would “accelerate the company’s innovation capabilities in enzyme engineering, fermentation and bio-process development.”
He added that the move would also support Kerry in the creation of “tastier, more sustainable and healthier products.”
